<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03934736</url>
  </required_header>
  <id_info>
    <org_study_id>DV2-HBV-24</org_study_id>
    <nct_id>NCT03934736</nct_id>
  </id_info>
  <brief_title>HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis</brief_title>
  <official_title>An Open-label, Single Arm Study, Evaluating the Immunogenicity and Safety of HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dynavax Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dynavax Technologies Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single arm study design to evaluate HEPLISAV-B® in adults with ESRD&#xD;
      who are initiating or undergoing hemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible participants will receive single doses of HEPLISAV-B® at Weeks 0, 4, 8, and 16 and&#xD;
      will be followed through Week 68 or end of study (EOS). The study is designed to evaluate the&#xD;
      immunogenicity over a 20-week period and safety over a 68-week period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 29, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Actual">October 23, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation of clinically significant adverse events</measure>
    <time_frame>Monitor for safety until Week 68 or EOS</time_frame>
    <description>To evaluate the proportion of subjects with treatment-emergent medically-attended adverse events (MAEs), serious adverse events (SAEs), immune-mediated adverse events of special interest (AESIs), acute myocardial infarctions (AMIs), and deaths</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of seroprotection rate (SPR)</measure>
    <time_frame>Week 20</time_frame>
    <description>To evaluate the immunogenicity induced by HEPLISAV-B® when administered according to the proposed dosing schedule, as measured by the SPR, defined as antibody to hepatitis B surface antigen (anti-HBs) ≥10 mIU/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of immunogenicity</measure>
    <time_frame>Weeks 4, 8, 16, 20</time_frame>
    <description>To evaluate the immunogenicity induced by HEPLISAV-B® as measured by the percentage of subjects with anti-HBs concentration ≥100 mIU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of immunogenicity</measure>
    <time_frame>Weeks 4, 8, 16, 20</time_frame>
    <description>To evaluate the immunogenicity induced by HEPLISAV-B® as measured by the serum anti-HBs geometric mean concentration (GMC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of immunogenicity</measure>
    <time_frame>Weeks 4, 8, 16, 20</time_frame>
    <description>To evaluate the immunogenicity induced by HEPLISAV-B® at each study visit through 20 weeks after the first dose of study vaccine as measured by the SPR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>End Stage Renal Disease on Dialysis (Diagnosis)</condition>
  <arm_group>
    <arm_group_label>HEPLISAV-B®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 0.5 mL HEPLISAV-B® administered intramuscularly in the deltoid muscle at Week 0 (Visit 1), Week 4 (Visit 2), Week 8 (Visit 3), and Week 16 (Visit 4).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEPLISAV-B®</intervention_name>
    <description>HEPLISAV-B®, a licensed, commercially-available hepatitis B vaccine consisting of the adjuvant cytidine phosphoguanosine (CpG) 1018 combined with the antigen recombinant hepatitis B surface antigen (rHBsAg).</description>
    <arm_group_label>HEPLISAV-B®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects at least 18 years of age&#xD;
&#xD;
          -  Laboratory confirmed negative serology result to hepatitis B virus (HBV) surface&#xD;
             antigen (HBsAg), antibody to hepatitis B surface antigen (anti-HBs), and antibody to&#xD;
             hepatitis B core antigen (anti-HBc) prior to first study injection&#xD;
&#xD;
          -  Must be clinically stable and in the opinion of the investigator able to comply with&#xD;
             all study procedures&#xD;
&#xD;
          -  Must be able and willing to provide informed consent&#xD;
&#xD;
          -  Receiving hemodialysis or will initiate hemodialysis within 4 weeks of first study&#xD;
             injection&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must consistently use an acceptable method of&#xD;
             contraception or confirm in writing she will abstain from sexual activity from the&#xD;
             Screening visit through 4 weeks after the last dose of study injection. Acceptable&#xD;
             birth control methods include but are not limited to oral contraceptive medication, an&#xD;
             intrauterine device (IUD), an injectable contraceptive (such as medroxyprogesterone&#xD;
             acetate or Depo-Provera®), a birth control patch, or a barrier method (such as condom&#xD;
             or diaphragm with spermicide).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous receipt of any hepatitis B vaccine&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection or&#xD;
             antibody to HIV or HCV&#xD;
&#xD;
          -  History of sensitivity to any component of study vaccine&#xD;
&#xD;
          -  Substance or alcohol abuse that in the opinion of the investigator would interfere&#xD;
             with compliance or with interpretation of the study results&#xD;
&#xD;
          -  Recent or ongoing history of febrile illness (within 7 days of the first study&#xD;
             injection)&#xD;
&#xD;
          -  Has received any of the following prior to the first study injection:&#xD;
&#xD;
               -  Within 14 days:&#xD;
&#xD;
                  a. Any inactivated vaccine&#xD;
&#xD;
               -  Within 28 days:&#xD;
&#xD;
                    1. Systemic corticosteroids (more than 3 consecutive days) or other&#xD;
                       immunomodulatory or immune suppressive medication with the exception of&#xD;
                       inhaled steroids&#xD;
&#xD;
                    2. Any live virus vaccine&#xD;
&#xD;
                    3. Granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage&#xD;
                       colony-stimulating factor (GM-CSF)&#xD;
&#xD;
                    4. Any other investigational medicinal agent&#xD;
&#xD;
               -  Within 90 days:&#xD;
&#xD;
                    1. Blood products or immunoglobulin&#xD;
&#xD;
          -  If female and pregnant, nursing, or planning to become pregnant during the study&#xD;
&#xD;
          -  Undergoing chemotherapy or expected to receive chemotherapy during the study period&#xD;
&#xD;
          -  Has a medical condition considered by the investigator likely to interfere with the&#xD;
             subject's compliance or the interpretation of study assessments, including the&#xD;
             following laboratory abnormalities which the investigator may consider if severe:&#xD;
&#xD;
               -  Anemia&#xD;
&#xD;
               -  Thrombocytopenia&#xD;
&#xD;
               -  Leukocytosis&#xD;
&#xD;
               -  Neutropenia&#xD;
&#xD;
               -  Metabolic acidosis&#xD;
&#xD;
               -  Increased alanine aminotransferase (ALT) or aspartate aminotransferase (AST)&#xD;
&#xD;
               -  Hyperkalemia&#xD;
&#xD;
               -  Hypokalemia&#xD;
&#xD;
          -  Is scheduled to undergo a kidney transplant within 6 months of the first study&#xD;
             injection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall N Hyer, MD, PhD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Dynavax Technologies Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Bloomfield</city>
        <state>Connecticut</state>
        <zip>06002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <zip>06762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Roseville</city>
        <state>Michigan</state>
        <zip>48066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research or Affiliate</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ESRD</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>HEPLISAV-B</keyword>
  <keyword>Prevention and Control</keyword>
  <keyword>HBV Vaccine</keyword>
  <keyword>Hepatitis B Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

